Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Buys $122,474.76 in Stock

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) major shareholder Braden Michael Leonard purchased 107,434 shares of Aclaris Therapeutics stock in a transaction that occurred on Monday, July 1st. The shares were bought at an average price of $1.14 per share, with a total value of $122,474.76. Following the completion of the transaction, the insider now owns 13,095,572 shares of the company’s stock, valued at approximately $14,928,952.08. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Braden Michael Leonard also recently made the following trade(s):

• On Thursday, June 27th, Braden Michael Leonard purchased 235,000 shares of Aclaris Therapeutics stock. The shares were bought at an average price of $1.15 per share, with a total value of $270,250.00.
• On Monday, June 17th, Braden Michael Leonard purchased 150,000 shares of Aclaris Therapeutics stock. The shares were bought at an average price of $1.13 per share, with a total value of $169,500.00.
• On Thursday, June 13th, Braden Michael Leonard purchased 528,621 shares of Aclaris Therapeutics stock. The shares were bought at an average price of $1.15 per share, with a total value of $607,914.15.
• On Tuesday, June 11th, Braden Michael Leonard purchased 1,000,000 shares of Aclaris Therapeutics stock. The shares were bought at an average price of $1.08 per share, with a total value of $1,080,000.00.

Aclaris Therapeutics Stock Up 4.5 %

Shares of Aclaris Therapeutics stock traded up $0.05 on Monday, reaching $1.15. The company’s stock had a trading volume of 1,651,796 shares, compared to its average volume of 1,279,422. The stock has a 50-day moving average price of $1.16 and a 200-day moving average price of $1.17. The company has a market capitalization of $81.95 million, a P/E ratio of -1.06 and a beta of 0.27. Aclaris Therapeutics, Inc. has a 52-week low of $0.59 and a 52-week high of $11.12.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The company had revenue of $2.40 million for the quarter, compared to analyst estimates of $1.99 million. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. Sell-side analysts forecast that Aclaris Therapeutics, Inc. will post -0.78 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 2nd. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $22.25.

Hedge Funds Weigh In On Aclaris Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC acquired a new position in shares of Aclaris Therapeutics in the 3rd quarter valued at $309,000. Trexquant Investment LP purchased a new stake in shares of Aclaris Therapeutics in the 3rd quarter valued at $876,000. Corton Capital Inc. purchased a new stake in shares of Aclaris Therapeutics in the 3rd quarter valued at $102,000. Vanguard Group Inc. raised its holdings in shares of Aclaris Therapeutics by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,363,046 shares of the biotechnology company’s stock valued at $23,037,000 after buying an additional 33,482 shares during the period. Finally, Vontobel Holding Ltd. raised its holdings in shares of Aclaris Therapeutics by 128.8% in the 4th quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 17,040 shares during the period. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.